{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:39:58Z","timestamp":1786649998919,"version":"build-2736575974"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>\n                    A\n                    <jats:sc>BSTRACT<\/jats:sc>\n                  <\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aim:<\/jats:title>\n                    <jats:p>Non-alcohol fatty liver disease (NAFLD) is a metabolic disorder that represents the hepatic manifestation of systemic process, and is a strong risk factor for diabetes Meletus, whereas the presence of DM increases the severity of NAFLD\/NASH and its progression. Data on the impact of diabetes on NASH phenotype is sparse from northern India. We studied and compared the clinical profile of NALFD in the presence and absence of DM and the effect of diabetes on NASH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We did a cross-sectional analysis of data from NAFLD patients (n = 90) who were divided into diabetic and non-diabetic cohorts and their respective demographic, biochemical, imaging and histological features were recorded and compared.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Out of 90 patients, 53.3% were females with a mean age of 44 \u00b1 12 years. The mean BMI and WHR of the study cohort were 28.9 \u00b1 3.4 and 1.01 \u00b1 0.15, respectively. The current study showed that 35.8% were diabetics. The mean age and WHR were 52 \u00b1 11 years vs 40 \u00b1 10 years and 1.1 \u00b1 0.17 vs 0.99 \u00b1 0.09, respectively, in diabetic and non-diabetic NAFLD patients. Non-invasive fibrosis scores, including BARD (2.8 vs 1.73), FIB-4 (3.4 vs 2.2) and NFS (0.97 vs \u22121.13), were significantly higher in diabetic NAFLD compared to non-diabetic NAFLD (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.03). The histological grade of steatosis and fibrosis as depicted by the mean NAS score (5.7 \u00b1 1.2 vs 4.63 \u00b1 0.8) was higher in diabetic NAFLD vs non-diabetic NAFLD; however, only the fibrosis stage was statistically significant between the groups (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Despite the small no of cases, we should conclude that there is a bidirectional relationship between NAFLD and DM where the progression of one increases the rate of progression of other. Diabetic patients have higher risk of NASH and hence increased risk of liver related mortality and should be screened early for NAFLD\/NASH.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jfmpc.jfmpc_1208_23","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T09:03:29Z","timestamp":1736759009000},"page":"56-61","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Two faces of the same coin non alcoholic fatty liver disease; with and without diabetes: Comparative clinico pathological analysis: A cross sectional observational study"],"prefix":"10.4103","volume":"14","author":[{"given":"Syed","family":"Mushfiq","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Sher-I-Kashmir Institute of Medical Sciences, Srinagar J and K, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghulam Nabi","family":"Yatoo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sher-I-Kashmir Institute of Medical Sciences, Srinagar J and K, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilal Ahmad","family":"Mir","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, IGMC, Shimla, Himachal Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zubaida","family":"Rasool","sequence":"additional","affiliation":[{"name":"Department of Pathology Sher-I-Kashmir Institute of Medical Sciences, Srinagar J and K, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"key":"R1-20260109","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease:Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"R2-20260109","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.metabol.2016.01.008","article-title":"Similarities and differences between pediatric and adult nonalcoholic fatty liver disease","volume":"65","author":"Crespo","year":"2016","journal-title":"Metabol Clin Exp"},{"key":"R3-20260109","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis:A systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R4-20260109","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jhep.2004.02.013","article-title":"The spectrum expanded:Cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease","volume":"40","author":"Caldwell","year":"2004","journal-title":"J Hepatol"},{"key":"R5-20260109","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic Steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"R6-20260109","doi-asserted-by":"crossref","first-page":"126","DOI":"10.2174\/1574887109666141216111143","article-title":"Nonalcoholic fatty liver:Epidemiology and natural history","volume":"9","author":"Masarone","year":"2014","journal-title":"Rev Recent Clin Trials"},{"key":"R7-20260109","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.dld.2015.08.004","article-title":"Epidemiological modifiers of non-alcoholic fatty liver disease:Focus on high-risk groups","volume":"47","author":"Bellentani","year":"2015","journal-title":"Dig Liver Dis"},{"key":"R8-20260109","doi-asserted-by":"crossref","first-page":"e0174291","DOI":"10.1371\/journal.pone.0174291","article-title":"Bidirectional association between nonalcoholic fatty liver disease and type 2 diabetes in Chinese population:Evidence from the Dongfeng-Tongji cohort study","volume":"12","author":"Li","year":"2017","journal-title":"PLoS One"},{"key":"R9-20260109","doi-asserted-by":"crossref","first-page":"12082","DOI":"10.3748\/wjg.v20.i34.12082","article-title":"Nonalcoholic fatty liver disease:A comprehensive review of a growing epidemic","volume":"20","author":"Hassan","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R10-20260109","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"key":"R11-20260109","doi-asserted-by":"crossref","first-page":"774","DOI":"10.3390\/ijms17050774","article-title":"The natural course of non-alcoholic fatty liver disease","volume":"17","author":"Calzadilla Bertot","year":"2016","journal-title":"Int J Mol Sci"},{"key":"R12-20260109","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"R13-20260109","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S2468-1253(22)00061-9","article-title":"Quality standards for the management of non-alcoholic fatty liver disease (NAFLD):Consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group","volume":"7","author":"McPherson","year":"2022","journal-title":"Lancet Gastroenterology Hepatology"},{"key":"R14-20260109","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1007\/s10620-014-3031-8","article-title":"Ox NASH score correlates with histologic features and severity of nonalcoholic fatty liver disease","volume":"59","author":"Alkhouri","year":"2014","journal-title":"Dig Dis Sci"},{"key":"R16-20260109","doi-asserted-by":"crossref","first-page":"665","DOI":"10.4103\/2230-8210.113758","article-title":"Clinicopathological characteristics and metabolic profiles of nonalcoholic fatty liver disease in Indian patients with normal body mass index:Do they differ from obese or overweight non-alcoholic fatty liver disease?","volume":"17","author":"Kumar","year":"2013","journal-title":"Indian J Endocr Metab"},{"key":"R17-20260109","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/hep.20092","article-title":"Ursodeoxycholic acid for treatment of non-alcoholic steatohepatitis:Results of a randomized trial","volume":"39","author":"Lindor","year":"2004","journal-title":"Hepatology"},{"key":"R18-20260109","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1053\/gast.2002.36572","article-title":"American Gastroenterological Association. AGA technical review on nonalcoholic fatty liver disease","volume":"123","author":"Sanyal","year":"2002","journal-title":"Gastroenterology"},{"key":"R19-20260109","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMra011775","article-title":"Non-alcoholic fatty liver disease","volume":"346","author":"Angulo","year":"2002","journal-title":"N Eng J Med"},{"key":"R20-20260109","doi-asserted-by":"crossref","first-page":"CR735","DOI":"10.12659\/MSM.883601","article-title":"The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease","volume":"18","author":"Cicho\u017c-Lach","year":"2012","journal-title":"Med Sci Monit"},{"key":"R21-20260109","doi-asserted-by":"crossref","first-page":"1224-9","DOI":"10.1016\/j.cgh.2009.06.007","article-title":"Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease","volume":"7","author":"Hossain","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R22-20260109","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S1542-3565(04)00014-X","article-title":"Nonalcoholic fatty liver disease in patients with type 2 diabetes","volume":"2","author":"Younossi","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R23-20260109","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/hep.28123","article-title":"Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009","volume":"62","author":"Younossi","year":"2015","journal-title":"Hepatology"},{"key":"R24-20260109","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1007\/s10620-013-2743-5","article-title":"Predictors of all-cause mortality and liverrelated mortality in patients with non-alcoholic fatty liver disease (NAFLD)","volume":"58","author":"Stepanova","year":"2013","journal-title":"Dig Dis Sci"},{"key":"R25-20260109","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","article-title":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis","volume":"10","author":"Anstee","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"}],"container-title":["Journal of Family Medicine and Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_1208_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:00:55Z","timestamp":1786647655000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_1208_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_1208_23","relation":{},"ISSN":["2249-4863","2278-7135"],"issn-type":[{"value":"2249-4863","type":"print"},{"value":"2278-7135","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2023-07-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}